SEC Form 4 · accession 0001209191-17-030214
CymaBay Therapeutics, Inc. · CBAY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Menold
Officer — Vice President, Finance
Period of report
May 3, 2017
Accepted (ET)
May 5, 2017 · 12:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001042074
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.45 | May 3, 2017 | A | 35,000 | A | — | May 2, 2027 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F1The shares subject to the option shall become vested and exercisable according to the following schedule: 25% of the shares subject to the option shall vest on April 27, 2018, and the remaining shares shall vest in equal monthly installments over the next 36 months.